{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:43:25Z","timestamp":1776231805911,"version":"3.50.1"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There are relatively well-substantiated concepts regarding the differences in the clinical course of metastatic colorectal cancer depending on the primary tumor localization: right- and left-sided (including rectal). However, many clinical trials demonstrate clear differences in the selected efficacy of adjuvant chemotherapy in the treatment of rectal versus colon cancer. We hypothesize that there are significant differences in long-term outcomes between patients with metastatic rectal cancer (RC) and those with left-sided colon cancer (LSCC) that may depend on the genetic profile of the primary tumor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>155 patients with synchronous metastases of LSCC and 96 patients with RC were selected for clinical analysis. The TCGA database was used to obtain information on mRNA expression from the \u201cComprehensive molecular characterization of human colon and rectal cancer\u201d study. 153 patients with LSCC and 41 patients with RC were included in this analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Clinical analysis characterized by a significantly more favorable course of the disease after I and I+II lines of chemotherapy for RC group, which may be associated with a higher expression of EBI3, IL-17A, and SOCS1 in the primary tumor. Also, the RC group is characterized by a higher sensitivity to anti-VEGF therapy, which can be explained by a higher expression of VEGF-A, VEGF-D, and KDR-VEGFR2 compared to the LSCC group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study shows that when analyzing the effectiveness of antitumor therapy in patients with colorectal cancer, it is necessary to distinguish not only between groups with cancer of the right and left colon, but also to consider rectal cancer as a third independent group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1797579","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:43:58Z","timestamp":1776228238000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Metastatic adenocarcinomas of left colon and rectum: differences in clinical outcome and gene expression"],"prefix":"10.3389","volume":"16","author":[{"given":"N. N.","family":"Semenov","sequence":"first","affiliation":[{"name":"State Budgetary Institution of Healthcare (SBIH) A.S. Loginov Moscow Clinical Scientific and Practical Center of the Department of Healthcare of the City of Moscow","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. G.","family":"Zhukova","sequence":"additional","affiliation":[{"name":"State Budgetary Institution of Healthcare (SBIH) A.S. Loginov Moscow Clinical Scientific and Practical Center of the Department of Healthcare of the City of Moscow","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. A.","family":"Yakovlev","sequence":"additional","affiliation":[{"name":"Massey Comprehensive Cancer Center, Virginia Commonwealth University (VCU) School of Medicine","place":["Richmond, VA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejca.2017.07.016","article-title":"Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes","volume":"84","author":"Stintzing","year":"2017","journal-title":"Eur J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-300865","article-title":"Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum","volume":"61","author":"Yamauchi","year":"2012","journal-title":"Gut"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2018.1442217","article-title":"Difference between right-sided and left-sided colorectal cancers: from embryology to molecular subtype","volume":"18","author":"Yang","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/annonc\/mdu560","article-title":"Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial","volume":"26","author":"Breugom","year":"2015","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(13)70599-0","article-title":"Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study","volume":"15","author":"Bosset","year":"2014","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2014.10.006","article-title":"No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-RT)","volume":"113","author":"Sainato","year":"2014","journal-title":"Radiother Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu147","article-title":"Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control","volume":"25","author":"Glynne-Jones","year":"2014","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andre","year":"2004","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.08.2974","article-title":"Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07","volume":"25","author":"Kuebler","year":"2007","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.60.9107","article-title":"Capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial","volume":"33","author":"Schmoll","year":"2015","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1200\/jco.2017.35.4_suppl.522","article-title":"Molecular variances between rectal and left-sided colon cancers","volume":"35","author":"Marshall","year":"2017","journal-title":"Am Soc Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4191","article-title":"Classification and characterization of microsatellite instability across 18 cancer types","volume":"22","author":"Hause","year":"2016","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.10.005","article-title":"The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer","volume":"48","author":"Hong","year":"2012","journal-title":"Eur J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","year":"2012","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt231","article-title":"Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings","volume":"24","author":"Kubicka","year":"2013","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv012","article-title":"Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial","volume":"26","author":"Masi","year":"2015","journal-title":"Ann Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02760","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study","volume":"41","author":"Saltz","year":"2023","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.09.013","article-title":"Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial","volume":"50","author":"Tabernero","year":"2014","journal-title":"Eur J Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/s1470-2045(15)70127-0","article-title":"Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu141","article-title":"Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer","volume":"25","author":"Douillard","year":"2014","journal-title":"Ann Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-0526","article-title":"Analysis of KRAS\/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer","volume":"21","author":"Peeters","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.06.015","article-title":"Impact of primary tumour location and RAS\/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial","volume":"101","author":"Hegewisch-Becker","year":"2018","journal-title":"Eur J Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.70.2.1143-1153.1996","article-title":"A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes","volume":"70","author":"Devergne","year":"1996","journal-title":"J Virol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2012.1669","article-title":"Function and cancer genomics of FAT family genes (review)","volume":"41","author":"Katoh","year":"2012","journal-title":"Int J Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2012.1669","article-title":"Emerging insights into Wnt\/Beta-catenin signaling in head and neck cancer","volume":"97","author":"Alamoud","year":"2018","journal-title":"J Dent Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.canlet.2017.03.033","article-title":"FAT1 prevents epithelial mesenchymal transition (EMT) via MAPK\/ERK signaling pathway in esophageal squamous cell cancer","volume":"397","author":"Hu","year":"2017","journal-title":"Cancer Lett"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1038\/s41467-018-04590-1","article-title":"Assembly and activation of the Hippo signalome by FAT1 tumor suppressor","volume":"9","author":"Martin","year":"2018","journal-title":"Nat Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2002.6475","article-title":"MUC17, a novel membrane-tethered mucin","volume":"291","author":"Gum","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.02.016","article-title":"Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancer","volume":"374","author":"Krishn","year":"2016","journal-title":"Cancer Lett"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2010.078717","article-title":"Expression of intestinal MUC17 membrane-bound mucin in inflammatory and neoplastic diseases of the colon","volume":"63","author":"Senapati","year":"2010","journal-title":"J Clin Pathol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3109\/10799893.2011.553836","article-title":"Methylation-mediated gene silencing of suppressor of cytokine signaling-1 (SOCS-1) gene in esophageal squamous cell carcinoma patients of Kashmir valley","volume":"31","author":"Hussain","year":"2011","journal-title":"J Recept Signal Transduct Res"},{"key":"B36","article-title":"Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis","volume":"9","author":"Okochi","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2010.13065","article-title":"Epigenetic alteration of the SOCS1 gene in hepatocellular carcinoma","volume":"140","author":"Chu","year":"2010","journal-title":"Swiss Med Wkly"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-08-1429","article-title":"Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis","volume":"68","author":"Huang","year":"2008","journal-title":"Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20521","article-title":"Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma","volume":"112","author":"Oshimo","year":"2004","journal-title":"Int J Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/43213","article-title":"A new protein containing an SH2 domain that inhibits JAK kinases","volume":"387","author":"Endo","year":"1997","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0097","article-title":"Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer","volume":"19","author":"Hashimoto","year":"2023","journal-title":"Future Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16050890","article-title":"Blood vessel-targeted therapy in colorectal cancer: current strategies and future perspectives","volume":"16","author":"Jacobsen","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.20944\/preprints202308.1044.v1","article-title":"Current status of angiogenesis inhibitors as second-line treatment for unresectable colorectal cancer","volume":"15","author":"Otsu","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713317","article-title":"Vascular endothelial growth factor-D (VEGF-D): an angiogenesis bypass in Malignant tumors","volume":"24","author":"Bokhari","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.4227","article-title":"Prognostic survival associated with left-sided vs right-sided colon cancer: A systematic review and meta-analysis","volume":"3","author":"Petrelli","year":"2017","journal-title":"JAMA Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e37613","article-title":"Ferroptosis-related oxaliplatin resistance in multiple cancers: Potential roles and therapeutic Implications","volume":"10","author":"Zhong","year":"2024","journal-title":"Heliyon"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3214105","article-title":"Epstein-Barr virus-induced gene 3 (EBI3) blocking leads to induce antitumor cytotoxic T lymphocyte response and suppress tumor growth in colorectal cancer by bidirectional reciprocal-regulation STAT3 signaling pathway","volume":"2016","author":"Liang","year":"2016","journal-title":"Mediators Inflammation"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5588043","article-title":"Low EBI3 expression promotes the Malignant degree of gastric cancer","volume":"2022","author":"Gu","year":"2022","journal-title":"Dis Markers"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8272","article-title":"Downregulation of Epstein-Barr virus-induced gene 3 is associated with poor prognosis of hepatocellular carcinoma after curative resection","volume":"15","author":"Song","year":"2018","journal-title":"Oncol Lett"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2014.15.19.8469","article-title":"Lack of prognostic significance of SOCS-1 expression in colorectal adenocarcinomas","volume":"15","author":"Ayyildiz","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgad060","article-title":"SOCS1 acts as a ferroptosis driver to inhibit the progression and chemotherapy resistance of triple-negative breast cancer","volume":"44","author":"Wang","year":"2023","journal-title":"Carcinogenesis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12906-021-03425-9","article-title":"Revealing the potential mechanism of Astragalus membranaceus improving prognosis of hepatocellular carcinoma by combining transcriptomics and network pharmacology","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Complement Med Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.06.003","article-title":"Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications","volume":"185","author":"Stockwell","year":"2022","journal-title":"Cell"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-178","article-title":"Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer","volume":"10","author":"Sasi","year":"2010","journal-title":"BMC Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8675","article-title":"Correlation of SOCS-1 gene with onset and prognosis of breast cancer","volume":"16","author":"Lv","year":"2018","journal-title":"Oncol Lett"},{"key":"B56","doi-asserted-by":"publisher","first-page":"995","DOI":"10.5152\/tjg.2022.211071","article-title":"Interleukin-17A mRNA expression is associated with the prognosis of patients with colorectal cancer: A pooled meta-analysis","volume":"33","author":"Yang","year":"2022","journal-title":"Turk J Gastroenterol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210330","article-title":"Identification of homozygous deletions of tumor suppressor gene FAT in oral cancer using CGH-array","volume":"26","author":"Nakaya","year":"2007","journal-title":"Oncogene"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-5","article-title":"Frequent loss of heterozygosity and altered expression of the candidate tumor suppressor gene 'FAT' in human astrocytic tumors","volume":"9","author":"Chosdol","year":"2009","journal-title":"BMC Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.319","article-title":"The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis-relapse samples of precursor B-cell acute lymphoblastic leukemia","volume":"26","author":"de Bock","year":"2012","journal-title":"Leukemia"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.4156","article-title":"VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab","volume":"14","author":"Moehler","year":"2008","journal-title":"World J Gastroenterol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1797579\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:44:08Z","timestamp":1776228248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1797579\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":60,"alternative-id":["10.3389\/fonc.2026.1797579"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1797579","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"article-number":"1797579"}}